{"id":15951,"date":"2022-09-13T16:28:42","date_gmt":"2022-09-13T15:28:42","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&p=15951"},"modified":"2023-03-06T14:56:47","modified_gmt":"2023-03-06T14:56:47","slug":"janwillem-kocks-goals-and-achievements-of-the-international-primary-care-respiratory-group-ipcrg","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/lung-health\/conference-hub\/janwillem-kocks-goals-and-achievements-of-the-international-primary-care-respiratory-group-ipcrg\/","title":{"rendered":"Janwillem Kocks: Goals and Achievements of the International Primary Care Respiratory Group (IPCRG)"},"content":{"rendered":"
The International Primary Care Respiratory Group (IPCRG) is a global charitable organisation with the goal of improving prevention, diagnosis and care of respiratory diseases in the primary care setting.<\/p>\n
touchRESPIRATORY were delighted to catch up with the IPCRG Past-President Prof. Janwillem Kocks<\/strong> (GPRI & University of Groningen, Groningen, Netherlands; OPRI Singapore, Singapore) to learn more around the goals of the IPCRG and their major achievements over the past year.<\/p>\n Questions<\/strong><\/p>\n Disclosures:<\/strong> Janwillem Kocks discloses receiving grant\/ research support from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GSK, TEVA, Valneva; serving on advisory boards for AstraZeneca; receiving honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GSK, TEVA, Mundi Pharma, MSD, COVIS Pharma; Janwillem Kocks holds <5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute.<\/p>\n\n